Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Lancet HIV. 2023;10(4):e230-e243.
30 April 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Lancet HIV. 2023;10(4):e230-e243.
30 April 2023
CAPRISA was formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York.
CAPRISA is a designated UNAIDS Collaborating Centre for HIV Research and Policy; and is the South African Department of Science and Innovation and the National Research Foundation‘s designated Centre of Excellence in HIV Prevention. Read more
We use cookies to make your experience with us better. By continuing to use our website, you are agreeing to our use of cookies. To find out more see our privacy policy.
Close